ArticleJournal of proteome research2014
Protein and site specificity of fucosylation in liver-secreted glycoproteins.
Article in Journal of proteome research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 34 citations in OpenAlex.
- The role ofActa pharmaceutica Sinica. B · 2024Review
- Mass spectrometry based biomarkers for early detection of HCC using a glycoproteomic approach.Advances in cancer research · 2023Review
- Modeling and integration of N-glycan biomarkers in a comprehensive biomarker data model.Glycobiology · 2022Article
- A Fucosylated Glycopeptide as a Candidate Biomarker for Early Diagnosis of NASH Hepatocellular Carcinoma Using a Stepped HCD Method and PRM Evaluation.Frontiers in oncology · 2022Article
- PRM-MS Quantitative Analysis of IsomericMetabolites · 2021Article
- FUT8 and Protein Core Fucosylation in Tumours: From Diagnosis to Treatment.Journal of Cancer · 2021Review
- Biomarkers for the Early Detection of Hepatocellular Carcinoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Comparison of Different HILIC Stationary Phases in the Separation of Hemopexin and Immunoglobulin G Glycopeptides and Their Isomers.Molecules (Basel, Switzerland) · 2020Article
- A wealth of genotype-specific proteoforms fine-tunes hemoglobin scavenging by haptoglobin.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- N-Glycan profiling of lung adenocarcinoma in patients at different stages of disease.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2020Article
- Machine Learning Classifies Core and Outer Fucosylation of N-Glycoproteins Using Mass Spectrometry.Scientific reports · 2020Article
- NIST Interlaboratory Study on Glycosylation Analysis of Monoclonal Antibodies: Comparison of Results from Diverse Analytical Methods.Molecular & cellular proteomics : MCP · 2020Article
- Global and site-specific analysis of protein glycosylation in complex biological systems with Mass Spectrometry.Mass spectrometry reviews · 2019Review
- Glycoproteomic markers of hepatocellular carcinoma-mass spectrometry based approaches.Mass spectrometry reviews · 2019Review
- The analysis of alpha-1-antitrypsin glycosylation with direct LC-MS/MS.Electrophoresis · 2018Article
- LC-MS/MS isomeric profiling of permethylated N-glycans derived from serum haptoglobin of hepatocellular carcinoma (HCC) and cirrhotic patients.Electrophoresis · 2017Article
- A pilot study of salivary N-glycome in HBV-induced chronic hepatitis, cirrhosis, and hepatocellular carcinoma.Glycoconjugate journal · 2017Article
- Changes in the Glycosylation of Kininogen and the Development of a Kininogen-Based Algorithm for the Early Detection of HCC.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017Article
- Changes in the expression of N- and O-glycopeptides in patients with colorectal cancer and hepatocellular carcinoma quantified by full-MS scan FT-ICR and multiple reaction monitoring.Journal of proteomics · 2017Article
- A procedure for the analysis of site-specific and structure-specific fucosylation in alpha-1-antitrypsin.Electrophoresis · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 2 countries.
Funding
Abstract
Chronic liver diseases are a serious health problem worldwide. One of the frequently reported glycan alterations in liver disease is aberrant fucosylation, which was suggested as a marker for noninvasive serologic monitoring. We present a case study that compares site specific glycoforms of four proteins including haptoglobin, complement factor H, kininogen-1, and hemopexin isolated from the same patient. Our exoglycosidase-assisted LC-MS/MS analysis confirms the high degree of fucosylation of some of the proteins but shows that microheterogeneity is protein- and site-specific. MSn analysis of permethylated detached glycans confirms the presence of LeY glycoforms on haptoglobin, which cannot be detected in hemopexin or complement factor H; all three proteins carry Lewis and H epitopes. Core fucosylation is detectable in only trace amounts in haptoglobin but with confidence on hemopexin and complement factor H, where core fucosylation of the bi-antennary glycans on select glycopeptides reaches 15-20% intensity. These protein-specific differences in fucosylation, observed in proteins isolated from the same patient source, suggest that factors other than up-regulation of enzymatic activity regulate the microheterogeneity of glycoforms. This has implications for selection of candidate proteins for disease monitoring and suggests that site-specific glycoforms have structural determinants, which could lead to functional consequences for specific subsets of proteins or their domains.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.